A Double-Blind, Randomized, Placebo Controlled, Parallel Group Study to Evaluate Biomarkers of Immunity to Varicella Zoster Virus Following Immunization With V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine or With ZOSTAVAX in Healthy Volunteers.

Trial Profile

A Double-Blind, Randomized, Placebo Controlled, Parallel Group Study to Evaluate Biomarkers of Immunity to Varicella Zoster Virus Following Immunization With V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine or With ZOSTAVAX in Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Dec 2013

At a glance

  • Drugs V 212 (Primary) ; Varicella zoster virus vaccine live
  • Indications Herpes zoster
  • Focus Pharmacodynamics
  • Sponsors Merck & Co
  • Most Recent Events

    • 13 Apr 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Nov 2009 Planned end date changed from 1 Feb 2010 to 1 Dec 2009 as reported by ClinicalTrials.gov.
    • 27 May 2009 Actual initiation date (Nov 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top